4006-776-356 出国就医服务电话

免费获得国外相关药品,最快 1 个工作日回馈药物信息

出境医 / 临床实验 / a Low-residue Diet for Bowel Preparation

a Low-residue Diet for Bowel Preparation

Study Description
Brief Summary:
Previous researches demonstrated that a prepackaged low-residue diet (LRD) could achieve better bowel preparation quality compared with a self-prepared LRD. However, up to now, there has been no widely acceptable standard of LRD for bowel preparation. Moreover, these prepackaged LRD adopted in previous studies mainly consisted of traditional foods without further processing. Recently, a prepackaged LRD for Special Medical Purpose was specifically designed for bowel preparation. This trail was to compare the impact of the prepackaged LRD on bowel preparation for colonoscopy with self-prepared LRD by patients.

Condition or disease Intervention/treatment Phase
Colon Polyp Colorectal Adenoma Dietary Supplement: Prepackaged Low-residue diet Dietary Supplement: Self-prepared Low-residue diet Not Applicable

Study Design
Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 800 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Care Provider, Outcomes Assessor)
Primary Purpose: Diagnostic
Official Title: Effect of a Prepackaged Low-residue Diet on Bowel Preparation for Colonoscopy
Actual Study Start Date : May 10, 2019
Estimated Primary Completion Date : December 10, 2019
Estimated Study Completion Date : December 31, 2019
Arms and Interventions
Arm Intervention/treatment
Experimental: prepackaged Low-residue diet group
The prepackaged Low-residue diet (Maifu Nutrition Technology Co. Ltd, Beijing, China). One package of the prepackaged Low-residue diet contained quantity of heat amounts to 268 kilocalories with 12.0 g of protein, 9.6 g of lipid, and 34.1 g of carbohydrate.
Dietary Supplement: Prepackaged Low-residue diet
Subjects in the prepackaged Low-residue diet group were given three packages of the prepackaged Low-residue diet, and instructed to ingest one package per meal without any other food being allowed in the day prior to colonoscopy.

Active Comparator: self-prepared Low-residue group
Subjects in the self-prepared Low-residue diet group were instructed to follow and prepare an Low-residue diet in the day prior to colonoscopy
Dietary Supplement: Self-prepared Low-residue diet
Subjects in the self-prepared Low-residue diet group were instructed to follow and prepare an Low-residue diet in the day prior to colonoscopy.

Outcome Measures
Primary Outcome Measures :
  1. Boston bowel preparation scale (BBPS) scores [ Time Frame: 30 mins ]
    BBPS was developed to evaluate the quality of colon preparation and was used in our previous study. Each section of the colon (i.e. the right, the transverse, and the rectosigmoid colon) was rated (0, very poor; 1, poor; 2, good; and 3, very good). Adequate bowel of bowel preparation was defined as a total BBPS score ≥ 6 and all colon segments BBPS ≥ 2. Inadequate bowel preparation was defined as any colon segment BBPS ≤ 1.

  2. adequate bowel preparation rate [ Time Frame: 30 mins ]
    Adequate bowel of bowel preparation was defined as a total BBPS score ≥ 6 and all colon segments BBPS ≥ 2. Inadequate bowel preparation was defined as any colon segment BBPS ≤ 1


Secondary Outcome Measures :
  1. adenoma detection rate (ADR) [ Time Frame: 30 mins ]
    adenoma detection rate is the number of patients with at least one adenoma, divided by the total number of patients.

  2. preparation completion rate [ Time Frame: 1 day ]
    preparation completion rate is the number of patients ingest more than 90% laxative, divided by the total number of patients.


Eligibility Criteria
Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients whose age is between 18-75.
  • Patients who have indications for screening, surveillance and diagnostic colonoscopy.
  • Patients who have signed inform consent form

Exclusion Criteria:

  • Patients who have undergone colonic resection
  • Patients with intracranial and/or central nervous system disease, including cerebral infarction and cerebral hemorrhage.
  • Patients with severe chronic cardiopulmonary and renal disease.
  • Patients who are unwilling or unable to consent.
  • Patients who are not suitable for colonoscopy
  • Patients who received urgent or therapeutic colonoscopy
  • Patients with pregnancy or breastfeeding, inflammatory bowel disease, polyposis of colon, BMI >30, colorectal cancer, diabetes mellitus, or intestinal obstruction
  • Patients who are taking aspirin, clopidogrel or other anticoagulants
  • Patients who are known allergies to any ingredients of the LRFP and polyethylene glycol-electrolyte lavage solution
Contacts and Locations

Contacts
Layout table for location contacts
Contact: Zhaoshen Li, M.D. 86-21-31161365 li.zhaoshen@hotmail.com
Contact: Yu Bai, M.D. +86-21-31161335 baiyu1998@hotmail.com

Locations
Layout table for location information
China
Changhai Hospital, Second Military Medical University Recruiting
Shanghai, China, 200433
Contact: bai yu, M.D    86-21-81873241    baiyu1998@hotmail.com   
Contact: zhao shengbing, M.D    86-21-81873241    zhaoshengbing@hotmail.com   
Sponsors and Collaborators
Changhai Hospital
Qilu Hospital of Shandong University
Jinan Military General Hospital
Wuhan TongJi Hospital
Zhejiang University
First Affiliated Hospital, Sun Yat-Sen University
The First Affiliated Hospital with Nanjing Medical University
West China Hospital
Investigators
Layout table for investigator information
Principal Investigator: Zhaoshen Li, M.D. Changhai Hospital
Tracking Information
First Submitted Date  ICMJE May 8, 2019
First Posted Date  ICMJE May 9, 2019
Last Update Posted Date August 14, 2019
Actual Study Start Date  ICMJE May 10, 2019
Estimated Primary Completion Date December 10, 2019   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: May 14, 2019)
  • Boston bowel preparation scale (BBPS) scores [ Time Frame: 30 mins ]
    BBPS was developed to evaluate the quality of colon preparation and was used in our previous study. Each section of the colon (i.e. the right, the transverse, and the rectosigmoid colon) was rated (0, very poor; 1, poor; 2, good; and 3, very good). Adequate bowel of bowel preparation was defined as a total BBPS score ≥ 6 and all colon segments BBPS ≥ 2. Inadequate bowel preparation was defined as any colon segment BBPS ≤ 1.
  • adequate bowel preparation rate [ Time Frame: 30 mins ]
    Adequate bowel of bowel preparation was defined as a total BBPS score ≥ 6 and all colon segments BBPS ≥ 2. Inadequate bowel preparation was defined as any colon segment BBPS ≤ 1
Original Primary Outcome Measures  ICMJE
 (submitted: May 8, 2019)
  • Boston bowel preparation scale (BBPS) scores [ Time Frame: 30 mins ]
    BBPS scores is to evaluate bowel preparation quality during colonoscopy.
  • adequate bowel preparation rate [ Time Frame: 30 mins ]
    adequate bowel preparation rate is the number of patients with adequate bowel preparation (BBPSs ≥ 6 ), divided by the total number of patients.
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: May 8, 2019)
  • adenoma detection rate (ADR) [ Time Frame: 30 mins ]
    adenoma detection rate is the number of patients with at least one adenoma, divided by the total number of patients.
  • preparation completion rate [ Time Frame: 1 day ]
    preparation completion rate is the number of patients ingest more than 90% laxative, divided by the total number of patients.
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE a Low-residue Diet for Bowel Preparation
Official Title  ICMJE Effect of a Prepackaged Low-residue Diet on Bowel Preparation for Colonoscopy
Brief Summary Previous researches demonstrated that a prepackaged low-residue diet (LRD) could achieve better bowel preparation quality compared with a self-prepared LRD. However, up to now, there has been no widely acceptable standard of LRD for bowel preparation. Moreover, these prepackaged LRD adopted in previous studies mainly consisted of traditional foods without further processing. Recently, a prepackaged LRD for Special Medical Purpose was specifically designed for bowel preparation. This trail was to compare the impact of the prepackaged LRD on bowel preparation for colonoscopy with self-prepared LRD by patients.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Care Provider, Outcomes Assessor)
Primary Purpose: Diagnostic
Condition  ICMJE
  • Colon Polyp
  • Colorectal Adenoma
Intervention  ICMJE
  • Dietary Supplement: Prepackaged Low-residue diet
    Subjects in the prepackaged Low-residue diet group were given three packages of the prepackaged Low-residue diet, and instructed to ingest one package per meal without any other food being allowed in the day prior to colonoscopy.
  • Dietary Supplement: Self-prepared Low-residue diet
    Subjects in the self-prepared Low-residue diet group were instructed to follow and prepare an Low-residue diet in the day prior to colonoscopy.
Study Arms  ICMJE
  • Experimental: prepackaged Low-residue diet group
    The prepackaged Low-residue diet (Maifu Nutrition Technology Co. Ltd, Beijing, China). One package of the prepackaged Low-residue diet contained quantity of heat amounts to 268 kilocalories with 12.0 g of protein, 9.6 g of lipid, and 34.1 g of carbohydrate.
    Intervention: Dietary Supplement: Prepackaged Low-residue diet
  • Active Comparator: self-prepared Low-residue group
    Subjects in the self-prepared Low-residue diet group were instructed to follow and prepare an Low-residue diet in the day prior to colonoscopy
    Intervention: Dietary Supplement: Self-prepared Low-residue diet
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: May 8, 2019)
800
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE December 31, 2019
Estimated Primary Completion Date December 10, 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Patients whose age is between 18-75.
  • Patients who have indications for screening, surveillance and diagnostic colonoscopy.
  • Patients who have signed inform consent form

Exclusion Criteria:

  • Patients who have undergone colonic resection
  • Patients with intracranial and/or central nervous system disease, including cerebral infarction and cerebral hemorrhage.
  • Patients with severe chronic cardiopulmonary and renal disease.
  • Patients who are unwilling or unable to consent.
  • Patients who are not suitable for colonoscopy
  • Patients who received urgent or therapeutic colonoscopy
  • Patients with pregnancy or breastfeeding, inflammatory bowel disease, polyposis of colon, BMI >30, colorectal cancer, diabetes mellitus, or intestinal obstruction
  • Patients who are taking aspirin, clopidogrel or other anticoagulants
  • Patients who are known allergies to any ingredients of the LRFP and polyethylene glycol-electrolyte lavage solution
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 65 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Zhaoshen Li, M.D. 86-21-31161365 li.zhaoshen@hotmail.com
Contact: Yu Bai, M.D. +86-21-31161335 baiyu1998@hotmail.com
Listed Location Countries  ICMJE China
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03943758
Other Study ID Numbers  ICMJE Low-residue
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: Undecided
Responsible Party Zhaoshen Li, Changhai Hospital
Study Sponsor  ICMJE Changhai Hospital
Collaborators  ICMJE
  • Qilu Hospital of Shandong University
  • Jinan Military General Hospital
  • Wuhan TongJi Hospital
  • Zhejiang University
  • First Affiliated Hospital, Sun Yat-Sen University
  • The First Affiliated Hospital with Nanjing Medical University
  • West China Hospital
Investigators  ICMJE
Principal Investigator: Zhaoshen Li, M.D. Changhai Hospital
PRS Account Changhai Hospital
Verification Date August 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP

治疗医院